Journal articles
Grebely J; Petoumenos K; Hellard M; Matthews G; Suppiah V; Applegate TL; Yeung B; Marks P; Rawlinson WD; Lloyd AROLA; Booth D; Kaldor JM; George J; Dore GJ; Amin J; Cameron B; Acraman B; Dolan K; Bloch M; van Beek I; Li H; Madden A, 2010, 'Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection', Hepatology, 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P; Fraqueiro RL; Fraqueiro G; Pauchard CK; Pauchard M; Fontaine C; Michon C; Bensalem M; Perre P; Suaud I; Molina JM; Rachline A; Goujard C; Môle M; Arvieux C; Ratajczak M; Touam MB; Touam F; Girard PM; Lagneau JL; Raffi F; Hue H; Zucman D; de Truchis P; Berthe H; Levy Y; Jung C; Piketty C; Reynes J; Vidal M; Sereni D; Bloch M, 2009, 'Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: The 2IP ANRS 127 study', Journal of Antimicrobial Chemotherapy, 64, pp. 118 - 125, http://dx.doi.org/10.1093/jac/dkp146
Mitsuyasu RT; Merigan TC; Carr A; Zack JA; Winters MA; Workman C; Bloch M; Lalezari J; Becker S; Thornton L; Akil B; Khanlou H; Finlayson R; McFarlane R; Smith DE; Garsia R; Ma D; Law M; Murray JM; Von Kalle C; Ely JA; Patino SM; Knop AE; Wong P; Todd AV; Haughton M; Fuery C; Macpherson JL; Symonds GP; Evans LA; Pond SM; Cooper DA, 2009, 'Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34 + cells', Nature Medicine, 15, pp. 285 - 292, http://dx.doi.org/10.1038/nm.1932
Meads DM; McKenna SP; Bonney MA; Bloch MT, 2009, 'Further validation and responsiveness assessment of the herpes outbreak impact questionnaire and herpes symptom checklist', Value in Health, 12, pp. 397 - 400, http://dx.doi.org/10.1111/j.1524-4733.2008.00450.x
Martin A; Bloch MT; Amin J; Baker DL; Cooper DA; Emery S; Carr AD, 2009, 'Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial', Clinical Infectious Diseases, 49, pp. 1591 - 1601
Bodsworth N; Bloch M; McNulty A; Denham I; Doong N; Trottier S; Adena M; Bonney MA; Agnew J; Abdurahman I; Ajam A; Alexander R; Aung A; Barry S; Becker B; Belbin M; Bishop C; Bisshop F; Bourne C; Brett T; Brown K; Butler A; Carmody C; Chan D; Chuah J; Conway D; Daly C; Davies S; Davis C; Davis B; Dayan L; D'Bras L; Eisen D; Eliades C; Elisha B; Fairley C; Feiglin A; Freeman A; Furner V; Garland S; Genn W; Giannakopoulos J; Glass F; Gold J; Goswami J; Gowers A; Grech J; Hackney P; Hanson B; Hartnell K; Harvey C; Hasan M; Hawkins S; Heley S; Herbst D; Hespe C; Irlicht M; Isaacs A; Katahanas L; Kelly M; Komarowski P; Kostic G; Kozminsky M; Lagios K; Lee D; Lewis P; Liang T; Lyttle H; MacKellar-Michelmore H; MacLeod H; Marsh L; Marshall L; McCloskey J; McCurdy D; McEvoy P; McFarlane R; McKeegan P; McMurchie M; McNamee K; Medland N; Menon A; Meyerowitz C; Michaels W; Mobbs M; Montague A; Nicola N; Nurcombe C; O'Connor C; Ooi C; Ostrowskyl O; O'Sullivan M; Owen L; Papp K; Patten J; Panopoulous D; Pell C; Quan D; Quin J; Rhodes D; Rowles S, 2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study', Sexual Health, 5, pp. 219 - 225, http://dx.doi.org/10.1071/SH08013
Bodsworth N; Bloch M; McNulty A; Denham I; Doong N; Trottier S; Adena M; Bonney MA; Agnew J; Abdurahman I; Ajam A; Alexander R; Aung A; Barry S; Becker B; Belbin M; Bishop C; Bisshop F; Bourne C; Brett T; Brown K; Butler A; Carmody C; Chan D; Chuah J; Conway D; Daly C; Davies S; Davis C; Davis B; Dayan L; Donovan B; Eisen D; Eliades C; Elisha B; Fairley C; Feiglin A; Freeman A; Furner V; Garland S; Genn W; Giannakopoulos J; Glass F; Gold J; Goswami J; Gowers A; Grech J; Hackney P; Hanson B; Hartnell K; Harvey C; Hasan M; Hawkins S; Heley S; Herbst D; Hespe C; Irlicht M; Isaacs A; Katahanas L; Kelly M; Komarowski P; Kostic G; Kozminsky M; Lagios K; Lee D; Lewis P; Liang T; Lyttle H; Mackellar-Michelmore H; Macleod H; Marsh L; Marshall L; McCloskey J; McCurdy D; McEvoy P; McFarlane R; McKeegan P; McMurchie M; McNamee K; Medland N; Menon A; Meyerowitz C; Michaels W; Mobbs M; Montague A; Nicola N; Nurcombe C; O'Connor C; Ooi C; Ostrowskyl O; O'Sullivan M; Owen L; Papp K; Patten J; Panopoulous D; Pell C; Philpot R; Quan D; Quin J; Rhodes D, 2008, '2-Day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study (Sexual Health (2008) 5, 3, (219-225))', Sexual Health, 5, pp. 379, http://dx.doi.org/10.1071/SH08013_CO
D'Arminio Monforte A; Abrams D; Pradier C; Weber R; Reiss P; Bonnet F; Kirk O; Law M; De Wit S; Friis-Møller N; Phillips AN; Sabin CA; Lundgren JD; Collins S; Loeliger E; Tressler R; Weller I; Worm SW; Sjøl A; Sawitz LA; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjær J; De Wolf F; Zaheri S; Gras Athena L; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Eeftinck Schattenkerk JKM; Geerlings SE; Godfried MH; Lange JMA; Van Leth FC; Lowe SH; Van Der Meer JTM; Nellen FJB; Pogány K; Van Der Poll T; Ruys TA; Sankatsing ; Steingrover R; Van Twillert G; Van Der Valk M; Van Vonderen MGA; Vrouenraets SME; Van Vugt M; Wit FWMN; Van Eeden A; Ten Veen JH; Van Dam PS; Roos JC; Brinkman K; Frissen PHJ; Weigel HM; Mulder JW; Van Gorp ECM; Meenhorst PL; Mairuhu ATA; Veenstra J; Danner SA; Van Agtmael MA; Claessen FAP; Perenboom RM; Rijkeboer A; Richter C; Van Der Berg J; Van Leusen R; Vriesendorp R; Jeurissen FJF; Kauffmann RH; Koger ELW; Bravenboer B; Ten Napel CHH; Kootstra GJ; Sprenger HG; Miesen WMAJ; Doedens R; Scholvinck EH; Ten Kate RW; Van Houte DPF; Polee M; Kroon FP; Van Den B; Van Dissel JT; Schippers EF; Schreij G; Van De Geest S; Verbon A; Koopmans PP; Keuter M, 2008, 'HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies', AIDS, 22, pp. 2143 - 2153, http://dx.doi.org/10.1097/QAD.0b013e3283112b77
Sabin C; Monforte A; Friis-Moller N; Weber R; El-Sadr W; Reiss P; Kirk O; Mercie P; Law MG; De Wit S; Pradier C; Phillips A; Lundgren JD, 2008, 'Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction', Clinical Infectious Diseases, 46, pp. 1101 - 1110, http://dx.doi.org/10.1086/528862
Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H; Baker D; Bloch M; Bodsworth N; Cooper D; Workman C; Tsoukas C; Afani A; Perez J; Cortes J; Thitivichianlert S; Brown S; Galpin J; Hicks C; Kumar P; Lichtenstein K; Little S; Liporace R; Santana-Bagur J; Schwartz R; Steigbigel R; Tashima K, 2007, 'Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study', Journal of Acquired Immune Deficiency Syndromes, 46, pp. 125 - 133, http://dx.doi.org/10.1097/QAI.0b013e318157131c
Fox Z; Antunes F; Davey R; Gazzard B; Klimas N; Labriola A; Losso M; Neaton JD; Phillips A; Ruxrungtham K; Staszewski S; Weiss L; Lundgren DJ; Aguilar L; Angel EB; Aquilia S; Belloso W; Benetucci J; Bittar V; Cahn P; Casiro A; Contarelli J; Corral J; Daciuk L; David D; Ferrari I; Fridman D; Galache V; Guaragna G; Ivalo S; Laplume H; Lanusse I; Lasala MB; Lattes R; Lasovsky J; Lopardo G; Lourtau L; Lupo S; Maranzana A; Marson C; Massera L; Sanchez MDL; Somenzini C; Tocci M; Algar S; Anderson J; Baker D; Blavius K; Bloch M; Boyle M; Bradford D; Britton P; Carrall L; Carr A; Chuah J; Curry M; D'Arcy-Evans C; Dobson P; Doong N; Egan C; Ferguson W; Finlayson R; French M; Frater A; Gold J; Habel P; Haig K; Holland R; Hyland N; Hoy J; Hudson J; James R; Leung J; Lowe K; MacRae K; McMurchie M; Medland N; Miller S; Murray J; Newman R; David O; Patching J; Primrose R; Ree H; Richardson R; Rogers G; Roney J; Roth N; Sarangapany J; Shaw D; Silberberg C; Skett A; Vale R; Villella C; Walker A; Watson A; Wendt N; Wood H, 2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, 8, pp. 112 - 123, http://dx.doi.org/10.1111/j.1468-1293.2007.00440.x
Lowy M; Collins S; Bloch M; Gillman M; Lording D; Sutherland P; Wang H; Stecher V, 2007, 'Quality of erection questionnaire correlates: Change in erection quality with erectile function, hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction', Journal of Sexual Medicine, 4, pp. 83 - 92, http://dx.doi.org/10.1111/j.1743-6109.2006.00398.x
Emery S; Kelleher AD; Workman C; Puls R; Bloch MT; Baker D; Hoy JF; Ip S; Nalliah K; Ward L; Law MG; Cooper DA, 2007, 'Influence of IFN gamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy', Human Vaccines, 3, pp. 260 - 267
Collins S; Mertenskoetter T; Loeliger E; Tressler R; Weller I; Friis-Møller N; Worm SW; Sabin CA; Sjøl A; Lundgren JD; Sawitz A; Rickenbach M; Pezzotti P; Krum E; Gras L; Balestre E; Sundström A; Poll B; Fontas E; Torres F; Petoumenos K; Kjær J; Weber R; Reisswafaamel-Sadr P; Kirk O; Dabis F; Law MG; Pradier C; De Wit S; Akerlund B; Calvo G; Monforte ADA; Ledergerber B; Phillips AN; De Wolf F; Zaheri S; Bronsveld W; Hillebrand-Haverkort ME; Prins JM; Bos JC; Schattenkerk JKME; Geerlings SE; Godfried MH; Lange JMA; Van Leth FC; Lowe SH; Van Der Meer JTM; Nellen FJB; Pogány K; Van Der Poll T; Reiss P; Ruys TA; Sankatsing SU; Steingrover R; Van Twillert G; Van Der Valk M; Van Vonderen MGA; Vrouenraets SME; Van Vugt MV; Wit FWMN; Van Eeden A; Ten Veen JH; Van Dam PS; Roos JC; Brinkman K; Frissen PHJ; Weigel HM; Mulder JW; Van Gorp ECM; Meenhorst PL; Mairuhu ATA; Veenstra J; Danner SA; Van Agtmael MA; Claessen FAP; Perenboom RM; Rijkeboer A; Richter C; Van Der Berg J; Van Leusen R; Vriesendorp R; Jeurissen FJF; Kauffmann RH; Koger ELW; Bravenboer B; Ten Napel CHH; Kootstra GJ; Sprenger HG; Miesen WMAJ; Doedens R; Scholvinck EH; Ten Kate RW; Van Houte DPF; Polee M; Kroon FP; Van Den Broek PJ; Van Dissel JT; Schippers EF; Schreij G; Van De Geest S, 2006, 'Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D Study', Archives of Internal Medicine, 166, pp. 1632 - 1641, http://dx.doi.org/10.1001/archinte.166.15.1632
Gold J; Batterham MJ; Rekers H; Harms MK; Geurts TBP; Helmyr PME; Silva de Mendonça J; Carvalho LHF; Panos G; Pinchera A; Aiuti F; Lee C; Horban A; Gatell J; Phanuphak P; Prasithsirikul W; Gazzard B; Bloch M; Danner SA, 2006, 'Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting', HIV Medicine, 7, pp. 146 - 155, http://dx.doi.org/10.1111/j.1468-1293.2006.00358.x
Pett SL; Wand H; Law MG; Arduino R; Lopez JC; Knysz B; Pereira LC; Pollack S; Reiss P; Tambussi G; Abrams DI; Cooper DA; Darbyshire JH; Duncan WR; Emery S; Clifford Lane H; Lehrman S; Lundgren JD; Neaton JD; Aguilar L; Angel EB; Aquilia S; Belloso W; Benetucci J; Bittar V; Cahn P; Casiro A; Contarelli J; Corral J; Daciuk L; David D; Ines F; Fridman D; Galache V; Guaragna G; Ivalo S; Laplume H; Lasala MB; Lattes R; Lasovsky J; Lopardo G; Losso M; Lourtau L; Lupo S; Maranzana A; Marson C; Massera L; del Lujan Sanchez M; Somenzini C; Tocci M; Algar S; Anderson J; Austin D; Baker D; Blavius K; Bloch M; Boyle M; Bradford D; Carrall L; Carr A; Chuah J; Curry M; D'Arcy-Evans C; Dobson P; Doong N; Ferguson W; Finlayson R; French M; Gold J; Habel P; Hoy J; Hudson J; James R; Jeganathan S; Leung J; Lowe K; MacRae K; Mallal S; McMurchie M; Medland N; Mijch A; Miller S; Murray J; Orth D; Patching J; Primrose R; Quan D; Rawlinson M; Ree H; Richardson R; Rogers G; Roney J; Roth N; Shaw D; Soo TM; Sowden D; Street A; Street A; Vale R, 2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, 7, pp. 70 - 85, http://dx.doi.org/10.1310/4733-ACQF-F3P4-2QAC
Bloch MT; Smith DE; Quan D; Kaldor JM; Zaunders J; Petoumenos K; Irvine K; Law MG; Grey PA; Finlayson R; Mcfarlane R; Kelleher AD; Carr AD; Cooper DA, 2006, 'The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (Pulse)', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 42, pp. 192 - 202
Kinloch-De Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Cooper DA; Perrin L, 2005, 'Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection', Journal of Infectious Diseases, 192, pp. 607 - 617, http://dx.doi.org/10.1086/432002
Chee CC; Mortier E; Dupont C; Bloch M; Simonpoli AM; Rouveix E, 2005, 'Medical and social differences between French and migrant patients consulting for the first time for HIV infection', AIDS Care Psychological and Socio Medical Aspects of AIDS HIV, 17, pp. 516 - 520, http://dx.doi.org/10.1080/09540120412331291760
Winston A; Bloch MT; Carr AD; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387
Ray J; Marriott D; Bloch MT; McLachlan AJ, 2005, 'Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic', British Journal of Clinical Pharmacology, 60, pp. 291 - 299
Van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJP; Schechter M; Murphy RL; Horban A; Hall DB; Lange JMA; Reiss P, 2004, 'Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1', Plos Medicine, 1, pp. 064 - 074, http://dx.doi.org/10.1371/journal.pmed.0010019
Martin A; Smith D; Carr A; Hoy J; Chuah J; Mallal S; Law M; Clements M; Cooper DA; Macrae K; James R; Mijch A; McCormack C; Baker D; McLeod H; Kidd J; McFarlane R; Vale R; Roth N; Wood H; Finlayson R; Bodsworth N; Wheatley D; Austin D; Bloch M; Frater A; Doong N; Hudson J; Anderson J; Patching J; Leung J; Lee W; Sharkey T; Wand H, 2004, 'Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study)', HIV Clinical Trials, 5, pp. 192 - 200, http://dx.doi.org/10.1310/0GU7-6X27-MMHE-5ALE
Mortier E; Toure S; Seyler C; Bloch M; Anglaret X, 2003, 'Urinary pH in HIV-infected adults in Ivory Coast and in France [3]', AIDS, 17, pp. 2003 - 2005, http://dx.doi.org/10.1097/00002030-200309050-00028
Levy Y; Durier C; Krzysiek R; Rabian C; Capitant C; Lascaux AS; Michon C; Oksenhendler E; Weiss L; Gastaut JA; Goujard C; Rouzioux C; Maral J; Delfraissy JF; Emilie D; Aboulker JP; Gougeon ML; Metro A; Viard JP; Bouchenafa K; Jung C; Mortier E; Bloch M; Chandemerle C; Gérard L; Martinie M; Kazatchkine M; Laureillard D; Dinh TT; Dalmas AM; Peretti D; Rannou MT; Bazin C; Verdon R; Six M; Goubin P; Vittecoq D; Escaut L; Malet M; Maignan A; Bouvet E; Prevot MH; Fournier I; Gaudebout C; Yéni P; Belarbi L; Mandet C; Zucman D; Majerholc C; Boue F; Estocq GA; Delavalle AM; Pasquali JL; Lalanne H; Bouchet-Delbos L; Chambenoit C; Carmagnat MV; Grangeot-Keros L; Ameisen JC; Estaquier J; Monnier D; Ferchal F; Girard PM; Laplanche A; Bazin B; Foubert V; Izard S; Martins J; Netzer E, 2003, 'Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial', AIDS, 17, pp. 343 - 351, http://dx.doi.org/10.1097/00002030-200302140-00008
Emery S; Abrams D; Cooper DA; Darbyshire JH; Lane HC; Lundgren JD; Neaton JD, 2002, 'The evaluation of subcutaneous proleukin® (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials', Control Clin Trials, 23, pp. 198 - 220
Kaufmann GR; Bloch MT; Finlayson RJ; Zaunders J; Smith DE; Cooper DA, 2002, 'The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy', AIDS, 16, pp. 359 - 367
Bloch M, 2001, 'Current tren HIV therapy', Current Therapeutics, 42, pp. 8 - 12
Bodsworth NJ; Bloch M; Bower M; Donnell D; Yocum R; The International Panretin® Gel KS Study Group , 2001, 'Phase III Vehicle-Controlled, Multi-Centered Study of Topical Alitretinoin Gel 0.1% in Cutaneous AIDS-Related Kaposi’s Sarcoma', American Journal of Clinical Dermatology, 2, pp. 77 - 87, http://dx.doi.org/10.2165/00128071-200102020-00004
Stewart GJ; Ashton LJ; Biti RA; Ffrench RA; Bennetts BH; Newcombe NR; Benson EM; Carr A; Cooper DA; Kaldor JM; Anderson B; Allworth A; Ashton L; Baker D; Batty G; Beveridge A; Bloch M; Bodsworth N; Carr A; Clare K; Cooper D; Cummins E; Cunningham P; Couldwell D; Deacon N; Doong N; Finlayson R; Ffrench R; Furner V; Huffam S; Kaldor J; Kidd J; Kelly M; Lloyd A; McFarlane R; McLean K; McNulty A; McPhee D; Michelmore H; McMurchic M; Mutimer K; Peterson J; Price R; Quan D; Quin J; Ree H; Robertson M; Roggensack M; Schroeder K; Smith D; Spencer D; Stewart G; Sullivan J; Ziegler J, 1997, 'Increased frequency of CCR-5 Delta 32 heterozygotes among long-term non-progressors with HIV-1 infection', AIDS, 11, pp. 1833 - 1838, http://dx.doi.org/10.1097/00002030-199715000-00007
Bloch MW; Smith DA; Nelson DL, 1989, 'Heart rate, activity, duration, and affect in added-purpose versus single-purpose jumping activities.', American Journal of Occupational Therapy Official Publication of the American Occupational Therapy Association, 43, pp. 25 - 30, http://dx.doi.org/10.5014/ajot.43.1.25
Conference Papers
Thiruvarudchelvan A; Hart-Brown L; Bloch M; Yates D, 2023, 'The Nintedanib in Progressive Pneumoconiosis Study (NiPPs): early data from Australia.', in Occupational and environmental health, European Respiratory Society, pp. PA3800 - PA3800, presented at ERS International Congress 2023 abstracts, http://dx.doi.org/10.1183/13993003.congress-2023.pa3800
Cahn P; Sax PE; Squires K; Molina JM; Ratanasuwan W; Rassool M; Bloch M; Xu X; Zhou Y; Homony B; Hepler D; Teppler H; Hanna GJ; Nguyen BY; Greaves W, 2018, 'Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: Week 96 results from ONCEMRK, a randomized, double-blind, noninferiority trial', in Journal of Acquired Immune Deficiency Syndromes, pp. 589 - 598, http://dx.doi.org/10.1097/QAI.0000000000001723
Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK; Bloch M; de Wit J; Carr A, 2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27403
Connor D; Greaves I; Porter K; Bloch M, 2013, '1067-1069 Pre-hospital spinal immobilisation: An initial consensus statement', in Emergency Medicine Journal, pp. 1067 - 1069, http://dx.doi.org/10.1136/emermed-2013-203207
Scott I; Porter K; Laird C; Greaves I; Bloch M, 2013, 'The prehospital management of pelvic fractures: Initial consensus statement', in Emergency Medicine Journal, pp. 1070 - 1072, http://dx.doi.org/10.1136/emermed-2013-203211
Bloch M; Martin A; Amin I; Emery S; Carr A; Baker D; Cooper DA, 2010, 'Predictors of limb fat changes in patients switched to tenofovir-emtricitabine or abacavir-lamivudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A7 - A7, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Michon C; Facy F; Boue F; Henry S; Bloch M, 1993, 'Evaluation of the medical follow-up in drug addicts with HIV infection. Report and preliminary results of a multicentric study in Ile-de-France', in Revue D Epidemiologie Et De Sante Publique, pp. S51 - S52
Conference Posters
Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK; Bloch M; de Wit J; Carr A, 2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', Milan, Italy, presented at The 16th European AIDS Conference, Milan, Italy, 25 October 2017 - 27 October 2017
Conference Presentations
Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK; Bloch M; de wit J; Carr A, 2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', presented at The Australasian HIV&AIDS Conference, Canberra Australia, 06 November 2017 - 08 November 2017
Conference Abstracts
Martinello M; Bartlett S; Dore G; Bopage R; Finlayson R; Baker D; Bloch M; Doyle J; Shaw D; Hajkowicz K; Read P; Filep E; Lin L; Yee J; Applegate T; Hellard M; Matthews G, 2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018
Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'FRI-194 DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in Journal of Hepatology, Elsevier, Vol. 66, pp. s495 - s496, http://dx.doi.org/10.1016/s0168-8278(17)31388-0
Preprints
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2018, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607
Dharan NJ; Yeh P; Bloch M; Yeung M; Baker D; Guinto J; Roth N; Ftouni S; Ognenovska K; Smith D; Hoy JF; Woolley I; Pell C; Templeton DJ; Fraser N; Rose N; Hutchinson J; Petoumenos K; Dawson S-J; Polizzotto MN; Dawson MA; Group FTAS, Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study, http://dx.doi.org/10.1101/2020.11.19.20235069
Dawson M; Dharan N; Yeh P; Bloch M; Yeung M; Baker D; Guinto J; Roth N; Ftouni S; Ognenovska K; Smith D; Hoy J; Woolley I; Pell C; Templeton D; Fraser N; Rose N; Hutchinson J; Petoumenos K; Dawson S-J; Polizzotto M, Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study, http://dx.doi.org/10.21203/rs.3.rs-106576/v1
Dharan NJ; Sasson SC; Ahlenstiel G; Andersen CR; Bloch M; Buckland G; Hamad N; Han WM; Kelleher AD; Long GV; Matthews GV; Mina MM; Papot E; Petoumenos K; Swaminathan S; Withers B; Yun J; Polizzotto MN, Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia, http://dx.doi.org/10.1101/2023.08.17.23293358
Back to profile page
https://orcid.org/0000-0002-1143-5013